DEVELOPMENT OF A MONKEY MODEL FOR TESTING OF ANTIVIRAL AGENTS AGAINST HIV-1
开发用于测试 HIV-1 抗病毒药物的猴子模型
基本信息
- 批准号:5200716
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AIDS therapy AIDS vaccines Macaca nemestrina antibody titering disease /disorder model genetic strain human immunodeficiency virus 1 model design /development neutralizing antibody nonhuman therapy evaluation polymerase chain reaction recombinant virus simian immunodeficiency virus virus DNA virus envelope virus infection mechanism western blottings
项目摘要
The development of an animal model system for infection and disease by
HIV-1 is essential for AIDS vaccine studies and intervention. Currently,
the only animal species which can be infected by HIV-1 is the chimpanzee;
however, no disease is produced. Due to the enormous cost of maintaining
a chimpanzee and the fact that this cannot be a disease model, a better
model is sought. We have investigated infection, replication,
persistence and clinical changes of HIV-1 in pig-tail macaques. In
addition studies are underway to characterize a novel HIV-1/SIV chimeric
virus, constructed in our laboratory, for its potential to replicate in
pig-tail and rhesus monkeys.
Four monkeys were inoculated with two isolates of HIV-1 which differ in
their env regions: two monkeys designated as PT86 and PT99 received LAV,
which is similar in its env to the laboratory adapted strain, HIV-1 IIIB;
and two monkeys designated as PT87 and PT89 received a primary isolate
(< 4 passages) which is similar in its env region to the MN strain, which
represents the majority of North American HIV-1 isolates. Only PT86 and
PT99 seroconverted. In case of PT86, an increasing antibody titer
against all the HIV-1 proteins was seen by Western Blot analysis which
has remained high at 68 weeks post inoculation (PI). Neutralizing
antibodies developed at 6 weeks PI. From the early test time points,
infectious HIV-1 was isolated from PBMCs at 4 weeks PI. PCR analysis of
PBMCs indicated RNA expression at early time points (4, 6, 8 weeks PI)
and again at 40 and 52 weeks PI. At 84 weeks PI, although PT86 has
remained clinically healthy, a downward trend in CD4/CD8 may be
occurring. In case of PT99, antibodies to only the env proteins were
detected; however no virus has been isolated and the CD4/CD8 is
stable. These results indicated that LAV infected and replicated in
PT86 whereas no evidence of replication was seen in PT99. We have
further analyzed the persistence of HIV-1 sequences in the inoculated
monkeys. The results of DNA PCR using HIV-1 gag primers indicated that
HIV-1 sequences were detected in the PBMCs of PT86 at all time points
tested for up to about a year post-inoculation (last time confirmed)
whereas the sequences in PT99 were consistently detected at early time
points and then sporadically. In case of PT 87 and PT 89 HIV-1 sequences
were detected reproducibly only at an early time point indicating
infection of the animals but lack of replication. These results confirm
that HIV-1 can infect but not replicate efficiently in monkeys.
Furthermore, there are host factors that must be considered in selection
of animals for development of an AIDS model.
感染和疾病的动物模型系统的开发,
HIV-1对于艾滋病疫苗研究和干预至关重要。 目前,
唯一能被HIV-1感染的动物是黑猩猩;
但不会产生疾病。 由于维护成本巨大,
一只黑猩猩,事实上,这不可能是一个疾病模型,
模式是寻求。 我们研究了感染,复制,
HIV-1在猪尾猕猴中的持久性和临床变化。在
另外的研究正在进行中,以表征一种新的HIV-1/SIV嵌合体
病毒,在我们的实验室构建,其复制的潜力,
猪尾猴和恒河猴。
四只猴子接种了两种HIV-1分离株,
它们的env区域:命名为PT86和PT99的两只猴子接受LAV,
其env与实验室适应株HIV-1 IIIB相似;
命名为PT87和PT89的两只猴子接受了初级分离株
(<4代),其env区域与MN菌株相似,
代表了大多数北美HIV-1分离株。 只有PT86和
PT99血清转化。 在PT86的情况下,增加的抗体滴度
免疫印迹分析显示,
在接种后68周(PI)仍然很高。 中和
在PI 6周产生抗体。 从早期的测试时间点来看,
感染性HIV-1在感染后4周从PBMC中分离。 pcr分析
PBMC在早期时间点(PI 4、6、8周)显示RNA表达
并在PI第40周和第52周再次进行。 在PI 84周时,尽管PT86具有
在临床上保持健康,CD4/CD8下降趋势可能是
正在发生。在PT99的情况下,仅针对env蛋白的抗体被检测到。
检测到;然而,没有分离出病毒,CD4/CD8是
稳定 这些结果表明,LAV感染和复制,
PT86,而在PT99中没有观察到复制的证据。我们有
进一步分析了HIV-1序列在接种的
猴子用HIV-1 gag引物进行DNA PCR的结果表明,
在所有时间点,PT86的PBMC中均检测到HIV-1序列
接种后长达约一年的检测(最后一次确认)
而PT 99中的序列在早期就被一致地检测到
点,然后零星地。 如果是PT 87和PT 89 HIV-1序列
仅在早期时间点可重复检测到,
动物感染,但缺乏复制。这些结果证实
HIV-1可以感染猴子,但不能在猴子体内有效复制。
此外,在选择时必须考虑宿主因素
用于开发艾滋病模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
A S KHAN其他文献
A S KHAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('A S KHAN', 18)}}的其他基金
STRUCTURAL AND FUNCTIONAL STUDIES OF MAMMALIAN ENDOGENOUS RETROVIRAL SEQUENCES
哺乳动物内源逆转录病毒序列的结构和功能研究
- 批准号:
3818206 - 财政年份:
- 资助金额:
-- - 项目类别:
STRUCTURAL AND FUNCTIONAL STUDIES OF MAMMALIAN ENDOGENOUS RETROVIRAL SEQUENCES
哺乳动物内源逆转录病毒序列的结构和功能研究
- 批准号:
3809632 - 财政年份:
- 资助金额:
-- - 项目类别:
DEVELOPMENT OF A MONKEY MODEL FOR TESTING OF ANTIVIRAL AGENTS AGAINST HIV-1
开发用于测试 HIV-1 抗病毒药物的猴子模型
- 批准号:
3770322 - 财政年份:
- 资助金额:
-- - 项目类别:
STUDY OF A MURINE RETROVIRUS FROM A PACKAGING CELL LINE USED IN GENE THERAPY
用于基因治疗的来自包装细胞系的鼠逆转录病毒的研究
- 批准号:
3770323 - 财政年份:
- 资助金额:
-- - 项目类别:
STRUCTURAL AND FUNCTIONAL ANALYSIS OF ENDOGENOUS PROVIRUSES OF MICE
小鼠内源原病毒的结构和功能分析
- 批准号:
3822045 - 财政年份:
- 资助金额:
-- - 项目类别:
DEVELOPMENT OF A MONKEY MODEL FOR TESTING OF ANTIVIRAL AGENTS AGAINST HIV-1
开发用于测试 HIV-1 抗病毒药物的猴子模型
- 批准号:
3748151 - 财政年份:
- 资助金额:
-- - 项目类别:
STUDY OF A MURINE RETROVIRUS FROM A PACKAGING CELL LINE USED IN GENE THERAPY
用于基因治疗的来自包装细胞系的鼠逆转录病毒的研究
- 批准号:
3748152 - 财政年份:
- 资助金额:
-- - 项目类别:
MOLECULAR ANALYSIS OF MAMMALIAN ENDOGENOUS RETROVIRAL SEQUENCES
哺乳动物内源性逆转录病毒序列的分子分析
- 批准号:
3792555 - 财政年份:
- 资助金额:
-- - 项目类别:
STRUCTURAL AND FUNCTIONAL STUDIES OF MAMMALIAN ENDOGENOUS RETROVIRAL SEQUENCES
哺乳动物内源逆转录病毒序列的结构和功能研究
- 批准号:
3790737 - 财政年份:
- 资助金额:
-- - 项目类别:
MOLECULAR BIOLOGY AND BIOCHEMICAL STRUCTRUE OF ENDOGENOUS PROVIRUSES OF MICE
小鼠内源性原病毒的分子生物学和生化结构
- 批准号:
4688492 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a
非人类灵长类艾滋病疫苗研究核心功能基因组学实验室
- 批准号:
8845051 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a
非人类灵长类艾滋病疫苗研究核心功能基因组学实验室
- 批准号:
8748807 - 财政年份:2013
- 资助金额:
-- - 项目类别:
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: PROJECT 4
广泛保护性艾滋病疫苗的综合方法:项目 4
- 批准号:
8357598 - 财政年份:2011
- 资助金额:
-- - 项目类别:
New HIV/AIDS vaccines employing inflammatory dendritic cells
使用炎症树突状细胞的新型艾滋病毒/艾滋病疫苗
- 批准号:
8234958 - 财政年份:2011
- 资助金额:
-- - 项目类别:
New HIV/AIDS vaccines employing inflammatory dendritic cells
使用炎症树突状细胞的新型艾滋病毒/艾滋病疫苗
- 批准号:
8139488 - 财政年份:2011
- 资助金额:
-- - 项目类别:
OPTIMIZE THE IMMUNOGENICITY OF MVA-BASED AIDS VACCINES
优化基于 MVA 的艾滋病疫苗的免疫原性
- 批准号:
8357426 - 财政年份:2011
- 资助金额:
-- - 项目类别:
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: PROJECT 4
广泛保护性艾滋病疫苗的综合方法:项目 4
- 批准号:
8172760 - 财政年份:2010
- 资助金额:
-- - 项目类别:
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: CORE B
广泛保护性艾滋病疫苗的综合方法:核心 B
- 批准号:
8172758 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Enhancing the Immunogenicity and Utility of MVA-Based AIDS Vaccines
增强基于 MVA 的艾滋病疫苗的免疫原性和实用性
- 批准号:
8075652 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Enhancing the Immunogenicity and Utility of MVA-Based AIDS Vaccines
增强基于 MVA 的艾滋病疫苗的免疫原性和实用性
- 批准号:
7927768 - 财政年份:2010
- 资助金额:
-- - 项目类别:














{{item.name}}会员




